SynNotch-CAR T Cells vs. Glioblastoma
Glioblastoma multiforme (GBM), the deadliest malignant brain tumor, also represents a large proportion of all cerebral neoplasms1. Despite strides in immunotherapy, including Chimeric Antigen Receptor [...]
Stony Brook Study on the Role of DNA Amplification in Cancer Chemoresistance Leverages KromaTiD dGH in-Site™ Technology
[Longmont, CO. February 6, 2024] —A Stony Brook University team of researchers led by Gábor Balázsi, PhD, has identified DNA amplification as a major cause [...]
Me2SO-Free Cryopreservation Tailored for CAR-NK Cells
Adoptive cell therapies like those based on CAR-T cells have demonstrated remarkable success against several different cancer types, even in advanced cases. Targeted diagnoses include [...]
Rareservoir: A Powerful Genomic Tool for Rare Disease Research
Despite significant strides in genetic research, we lack a clear understanding of whether many rare diseases may have genetic origins, and of what those origins [...]
Unbiased Visualization of Structural Rearrangements
DNA double-strand breaks (DSBs) and potential misrepair events can result from the use of gene editing tools like CRISPR/Cas systems. These misrepairs are associated with [...]
New Genotoxicity Concerns in Nickase-Based Editing Systems
In the context of gene editing applications, genotoxicity may be defined as, “the property of an agent able to alter the genetic function within a [...]
KromaTiD Webinar | Combining Synthetic and Evolutionary Biology Reveals DNA Therapy to Combat Cancer Chemoresistance
Register below for the KromaTiD Webinar | Combining Synthetic and Evolutionary Biology Reveals DNA Therapy to Combat Cancer Chemoresistance Drug resistance is still an ongoing [...]
The Longer-Term Effects of CAR-T Therapy
CAR T cell therapies have achieved substantial improvements in the prognoses of patients fighting advanced hematological malignancies, demonstrating robust efficacy in inducing durable remissions. While [...]
Mast Cells and Dendritic Cells as Cellular Immune Checkpoints
Solid tumors, with their intricate immune microenvironment, pose a formidable challenge to immunotherapy. Within this complex landscape, mast cells (MCs) and dendritic cells (DCs) emerge [...]
Pairing Immunotherapies: CAR-T and NK Cells
While immune checkpoint blockade therapies targeting T cells have shown promise, limitations arise in cases of tumor escape mechanisms, including HLA-I downregulation. Loss of HLA-I [...]